- Home
- AVIR vs SCPH Comparison
AVIR vs SCPH Comparison
Compare AVIR & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- SCPH
- Stock Information
- Founded
- AVIR 2012
- SCPH 2013
- Country
- AVIR United States
- SCPH United States
- Employees
- AVIR N/A
- SCPH N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- SCPH Health Care
- Exchange
- AVIR Nasdaq
- SCPH Nasdaq
- Market Cap
- AVIR 273.0M
- SCPH 173.6M
- IPO Year
- AVIR 2020
- SCPH 2017
- Fundamental
- Price
- AVIR $3.60
- SCPH $3.92
- Analyst Decision
- AVIR Hold
- SCPH Strong Buy
- Analyst Count
- AVIR 1
- SCPH 3
- Target Price
- AVIR $6.00
- SCPH $14.00
- AVG Volume (30 Days)
- AVIR 409.3K
- SCPH 289.6K
- Earning Date
- AVIR 08-06-2025
- SCPH 08-13-2025
- Dividend Yield
- AVIR N/A
- SCPH N/A
- EPS Growth
- AVIR N/A
- SCPH N/A
- EPS
- AVIR N/A
- SCPH N/A
- Revenue
- AVIR N/A
- SCPH $41,982,000.00
- Revenue This Year
- AVIR N/A
- SCPH $108.95
- Revenue Next Year
- AVIR N/A
- SCPH $73.83
- P/E Ratio
- AVIR N/A
- SCPH N/A
- Revenue Growth
- AVIR N/A
- SCPH 138.10
- 52 Week Low
- AVIR $2.46
- SCPH $1.94
- 52 Week High
- AVIR $4.15
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- AVIR 71.04
- SCPH 57.14
- Support Level
- AVIR $3.43
- SCPH $3.77
- Resistance Level
- AVIR $3.73
- SCPH $4.03
- Average True Range (ATR)
- AVIR 0.13
- SCPH 0.19
- MACD
- AVIR 0.03
- SCPH -0.06
- Stochastic Oscillator
- AVIR 73.04
- SCPH 31.82
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.